- Home
- / Nanjing King-Friend Biochemical Pharmaceutical
Nanjing King-Friend Biochemical Pharmaceutical
Stock Price
¥14.4
2024-10-29
Market Capitalization
¥23.3 B
2024-10-29
Revenue
¥4 B
FY, 2025
Nanjing King-Friend Biochemical Pharmaceutical Summary
Company Summary
- Overview
- Nanjing King-Friend Biochemical Pharmaceutical (NKF, 南京健友生化制药股份有限公司) is a company that specializes in the research, production, and sales of medicines and health products. It offers enoxaparin and dalteparin sodium and heparin calcium injections.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Nanjing, CN | view all locations
- Website
- https://www.nkf-pharma.com
- Cybersecurity rating
Table of Contents
LocationsView all
6 locations detected
Nanjing, Jiang Su Sheng HQ
China
No. 16, Xuefu Road
Chicago, IL
United States
8700 W Bryn Mawr #600S
Chengdu, Si Chuan Sheng
China
No. 9, No. 8, Kexin Road, Chengdu High-tech West District Comprehensive Free Trade Zone
Cork, CO
Ireland
Unit F, First Floor, Building 2100, Cork Airport Business Park
Milano, Lombardia
Italy
Via Paolo da Cannobio 9
Altrincham, England
United Kingdom
3rd Floor, 1 Ashley Road
Nanjing King-Friend Biochemical Pharmaceutical Financials
Summary Financials
- Revenue (Q1, 2026)
- ¥924.7M
- Gross profit (Q1, 2026)
- ¥296.1M
- Net income (Q1, 2026)
- ¥89.0M
- Cash (Q1, 2026)
- ¥2.3B
- EBIT (Q1, 2026)
- ¥132.6M
- Enterprise value
- $23.7B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026